Statistics in Biopharmaceutical Research

Papers
(The H4-Index of Statistics in Biopharmaceutical Research is 10. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)
ArticleCitations
Treatment Selection at Interim Analysis Based on a Correlated Early Endpoint in Adaptive Two-Stage Trials with a Primary Endpoint Based on Count Data35
DODII: Bayesian Dose Optimization Design for Randomized Phase II Trials23
U-MET: Utility-Based Dose Optimization Approach for Multiple-Dose Randomized Trial Designs23
Predicting Probability of Success for Phase III Trials via Propensity-Score-Based External Data Borrowing16
The Current Landscape of HTA Framework and Key Challenges14
Consistency Based Multiplicity Adjustment Approach—Multiple Doses in Phase III Studies13
Modified Simon’s Two-Stage Design for Phase IIA Clinical Trials in Oncology—Dynamic Monitoring and More Flexibility12
Joint Analysis of Longitudinal Ordinal Categorical Item Response Data and Survival Times with Cure Fraction11
We Need Subject Matter Expertise to Choose and Identify Causal Estimands: Comment on “Estimands for Recurrent Event Endpoints in the Presence of a Terminal Event”11
Bayesian and Frequentist Approaches to Rescuing Disrupted Trials: A Report from the NISS Ingram Olkin Forum Series on Unplanned Clinical Trial Disruptions10
A Basket Trial Design Based on Power Priors10
Missing Data Imputation for a Multivariate Outcome of Mixed Variable Types10
Some Multiplicity Adjustment Procedures for Clinical Trials with Sequential Design and Multiple Endpoints10
Design Strategy and Consideration for Oncology Dose-Optimization: An Industry Perspective10
0.025588035583496